Alecensa (alectinib) / Roche 
Welcome,         Profile    Billing    Logout  
 13 Diseases   52 Trials   52 Trials   3235 News 


«12345678910111213...3637»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Alecensa (alectinib) / Roche
    Trial completion, Trial completion date:  BLISS: Brazilian Lung Immunotherapy Study (clinicaltrials.gov) -  Oct 11, 2023   
    P2,  N=154, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023
  • ||||||||||  Trial completion date, Trial primary completion date, Tumor mutational burden:  The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (clinicaltrials.gov) -  Oct 3, 2023   
    P2,  N=400, Active, not recruiting, 
    Overall, national clinical practice follows international recommendations for the diagnosis and treatment of ALK-positive NSCLC. Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Dec 2024
  • ||||||||||  Review, Journal, Pan tumor:  ALK fusions in the pan-cancer setting: another tumor-agnostic target? (Pubmed Central) -  Sep 29, 2023   
    ALK inhibitor activity is also seen in neuroblastoma, which bear ALK mutations (rather than fusions/rearrangements), but response rates are lower (~10-20%). Current data suggests that ALK inhibitors have tissue-agnostic activity in neoplasms bearing ALK fusions/rearrangements.
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, Metastases:  Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure. (Pubmed Central) -  Sep 29, 2023   
    In cases of ALK-dependent resistance mutations, lorlatinib could be the first choice as it exhibits the broadest coverage of mutations that lead to resistance against second-generation ALK - TKIs, such as G1202R, and L1196M. In cases of no resistance mutations, atezolizumab, bevacizumab and platinum-based chemotherapy could be the alternative treatment option.
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  NCT Neuro Master Match - N (clinicaltrials.gov) -  Sep 28, 2023   
    P1/2,  N=228, Completed, 
    In cases of no resistance mutations, atezolizumab, bevacizumab and platinum-based chemotherapy could be the alternative treatment option. Recruiting --> Completed | N=350 --> 228 | Trial completion date: Sep 2024 --> Feb 2023 | Trial primary completion date: Sep 2023 --> Feb 2023
  • ||||||||||  Edurant (rilpivirine) / J&J, Alecensa (alectinib) / Roche
    Journal:  Photophysical Exploration of Alectinib and Rilpivirine: Insights from Theory and Experiment. (Pubmed Central) -  Aug 30, 2023   
    Lastly, Alectinib and Rilpivirine displayed green fluorescence in HeLa cells, suggesting the potential ability for biological imaging. Investigation using theoretical and experimental methods is certainly encouraged, given the particular significance of developing integrated diagnosis and treatment.
  • ||||||||||  Safety and Efficacy of Stereotactic Radiosurgery with Concurrent Targeted Systemic Therapy for Brain Metastases (Hall B2; In Person Only; Screen: 11) -  Aug 22, 2023 - Abstract #ASTRO2023ASTRO_663;    
    Although heterogeneous, patients treated with SRS/SRT and ongoing CNS-active targeted systemic therapies have on average >6 month intracranial PFS and little evidence of significant toxicity. We observed <6% G2+ radiation necrosis for this cohort, and no particular class of agent was associated with a significantly higher rate of G2+ radiation necrosis.
  • ||||||||||  Phase classification, Enrollment change:  SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) -  Aug 8, 2023   
    P1,  N=25, Not yet recruiting, 
    ALK-TKIs were associated with ILD; therefore, the risk of developing ILD after treatment with an ALK-TKI should be carefully considered in clinical settings. Phase classification: P2 --> P1 | N=131 --> 25
  • ||||||||||  Avastin (bevacizumab) / Roche, IBI-323 / Innovent Biologics, Alecensa (alectinib) / Roche
    Biomarker, Trial completion date, Trial primary completion date:  Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov) -  Aug 1, 2023   
    P2,  N=80, Not yet recruiting, 
    Thus, patients with ALK-positive NSCLC post second-generation ALK TKI remained on lorlatinib for a meaningful duration of time while their quality-of-life was preserved. Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Review, Journal:  Indole Antitumor Agents in Nanotechnology Formulations: An Overview. (Pubmed Central) -  Jul 29, 2023   
    Additionally, new drug delivery systems have been developed to protect the active principle from degradation and to direct the drug to the specific site for clinical use, thus reducing its toxicity. In the present work is an updated review of the recently approved indole-based anti-cancer agents and the nanotechnology systems developed for their delivery.
  • ||||||||||  Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
    First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_2864;    
    Treatment-related adverse events were usually mild, and treatment discontinuation due to adverse events was rare in both groups. Conclusions Alectinib and brigatinib had similar clinical benefits when used as the first-line treatment of NSCLC patients with ALK rearrangement in the real world.
  • ||||||||||  Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
    BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019) () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_2862;    
    Conclusions Alectinib and brigatinib had similar clinical benefits when used as the first-line treatment of NSCLC patients with ALK rearrangement in the real world. Background Brigatinib and alectinib are both next-generation ALK inhibitors (ALKi) showing efficacy in na
  • ||||||||||  Alecensa (alectinib) / Roche
    Alectinib for treatment-na () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_2854;    
    P2/3
    Concurrent TP53 mutation and high baseline ctDNA levels were associated with poorer prognosis; ctDNA clearance was associated with better outcomes. Table: 1361P
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
    Pooled efficacy and safety data of alectinib (A) vs. crizotinib (C) from the randomized phase III ALEX and J-ALEX trials () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_1815;    
    P3
    Grade ?3 adverse events occurred in 36% of pts with A vs 51% with C, 15% of pts discontinued A vs 20% C. Table: 186P Subgroup analysis Conclusions hTB is a prognostic and predictive factor in patients with advanced ALK+ NSCLC under ALK-inhibitors, while a BMI ?25 is linked to a reduced risk of death. Escalation strategies could be explored for hTB.